HER2-positive Metastatic Gastroesophageal Junction Research Articles

Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).

2564Background: The phase 2a, dose-finding JOSHUA study reported increased P clearance (CL; 37% lower P steady-state Cmin [Cmin,ss]) in pts with HER2+ mGEJC/GC vs metastatic breast cancer (MBC). Ba...